Etanercept in the Treatment of Patients with Primary Sjögren's Syndrome: A Pilot Study

Journal of Rheumatology

Volumn 31, Issue 1, 2004, Pages 96-101

  Zandbelt, Michiel M ^a,b   De Wilde, Peter C M ^a,b   Van Damme, Philip A ^a,b   Hoyng, Carel B ^a,b   Van De Putte, Leo B A ^a,b   Van Den Hoogen, Frank H J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Rheumatology ^*

Author keywords

Anti tumor necrosis factor alpha; Etanercept; Fatigue; Salivary gland biopsy; Sicca; Sj gren's syndrome

Indexed keywords

ETANERCEPT; INFLIXIMAB; PILOCARPINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CORNEA CELL; DOSE TIME EFFECT RELATION; DRY EYE; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION; FATIGUE; FEMALE; FLOW MEASUREMENT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE; MALE; MINOR SALIVA GLAND; PAROTITIS; PATIENT MONITORING; PLASMA CELL; PRIORITY JOURNAL; QUESTIONNAIRE; SALIVA LEVEL; SCHIRMER TEST; SCORING SYSTEM; SERODIAGNOSIS; SIDE EFFECT; SJOEGREN SYNDROME; STAINING; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTEMIC DISEASE; TEAR FILM;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMA CELLS; RECEPTORS, TUMOR NECROSIS FACTOR; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME;

EID: 0346057894     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Daniels TF, Aufdemorte TB, Greenspan JS. Histopathology of Sjögren's syndrome. In: Talal N, Moutsopoulos HM, Kassan SS, editors. Sjögren's syndrome: Clinical and immunological aspects. Berlin, Heidelberg: Springer Verlag; 1987:41-52.
2. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
3. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for $jögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
4. Bodeutsch C, de Wilde PC, Kater L, et al. Quantitative immunohistologic criteria are superior to the lymphocytic focus score criterion for the diagnosis of Sjögren's syndrome. Arthritis Rheum 1992;35:1075-87.
5. Zandbelt MM, Wentink JRM, de Wilde PCM, van Damme PhA, van de Putte LBA, van den Hoogen FHJ. The synergistic value of focus score and IgA% of sublabial salivary gland biopsy for the accuracy of the diagnosis of Sjögren's syndrome: a 10-year comparison. Rheumatology Oxford 2002;82:841-5.
6. Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary $jögren's syndrome. Ann Rheum Dis 1998;57:291-5.
7. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol 2000;29:341-8.
8. Vivino FB, Al Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intem Med 1999;159:174-81.
9. Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52:360-4.
10. Theander E, Horrobin DF, Jacobsson LT, Manthorpe R. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome. Scand J Rheumatol 2002;31:72-9.
11. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
12. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
13. Mease PJ, Goffe BS, Metz J, Vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
14. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
15. Sandbom WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
16. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9.
17. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol 1995;34:326-33.
18. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
19. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
20. Zandbelt MM, van den Hoogen FHJ, de Wilde PC, van den Berg PJS, Schneider HGF, van de Putte LBA. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsies following treatment with corticosteroids in Sjögren's syndrome. Ann Rheum Dis 2001;82:511-3.
21. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
22. Kalk WW, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, Nieuw Amerongen AV. Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis 2001;60:1110-6.
23. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
24. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
25. van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001;121:1242-6.
26. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.